Amarin Corporation News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.12.24	Amarin Appoints Peter Fishman As CFO (RTTNews)
29.10.24	Ausblick: Amarin mit Zahlen zum abgelaufenen Quartal (finanzen.net)
15.10.24	Erste Schätzungen: Amarin legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
30.07.24	Ausblick: Amarin stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
08.07.24	Amarin's Chinese Partner Gets NMPA's Approval For Vascepa For Cardiovascular Risk Reduction (RTTNews)
30.04.24	Ausblick: Amarin gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
16.04.24	Erste Schätzungen: Amarin verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
03.04.24	Amarin: IP Protection For VAZKEPA In Europe Now Extended Into 2039 - Quick Facts (RTTNews)
31.10.23	Ausblick: Amarin stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
02.08.23	Amarin Reports Second Quarter 2023 Financial Results (GlobeNewswire)
31.07.23	Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea (GlobeNewswire)
26.07.23	Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress (GlobeNewswire)
25.07.23	Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain (GlobeNewswire)
20.07.23	Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt (GlobeNewswire)
18.07.23	Amarin Corp Appoints Patrick Holt As President And CEO (RTTNews)
18.07.23	Amarin Appoints Patrick Holt as President and Chief Executive Officer (GlobeNewswire)
18.07.23	Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally (GlobeNewswire)
21.06.23	Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA) (GlobeNewswire)
01.06.23	Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China (GlobeNewswire)
12.05.23	Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events (GlobeNewswire)
03.05.23	Amarin Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
02.05.23	Ausblick: Amarin gewährt Anlegern Blick in die Bücher (finanzen.net)
19.04.23	Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 (GlobeNewswire)
17.04.23	Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors (GlobeNewswire)
04.04.23	Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health (GlobeNewswire)
16.03.23	Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) (GlobeNewswire)
06.03.23	Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC (GlobeNewswire)
05.03.23	Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event (GlobeNewswire)
01.03.23	Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
28.02.23	Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand (GlobeNewswire)
28.02.23	Ausblick: Amarin verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
27.02.23	Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC (GlobeNewswire)
22.02.23	Amarin to Present at Cowen's 43rd Annual Health Care Conference (GlobeNewswire)
21.02.23	Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023 (GlobeNewswire)
07.12.22	Amarin's Vazkepa Gets Approval From Swissmedic (RTTNews)
15.11.22	Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia (GlobeNewswire)
09.11.22	Amarin to Present at Jefferies London Healthcare Conference (GlobeNewswire)
07.11.22	Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care (GlobeNewswire)
27.10.22	Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
26.10.22	Ausblick: Amarin vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
20.10.22	Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors (GlobeNewswire)
20.10.22	Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022 (GlobeNewswire)
11.10.22	Amarin Board of Directors Issues Statement in Response to Sarissa (GlobeNewswire)
30.08.22	Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference (GlobeNewswire)
28.08.22	New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers (GlobeNewswire)
26.08.22	New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes (GlobeNewswire)
15.08.22	Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress (GlobeNewswire)
03.08.22	Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
02.08.22	Ausblick: Amarin öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
20.07.22	Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Amarin Corporation PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten